Table 1 Demographics and baseline characteristics of the enrolled subjects (included in the efficacy analysis)
Placebo | Ivermectin | P value | |||
|---|---|---|---|---|---|
(n = 26) | (n = 30) | ||||
95% CI | 95% CI | ||||
Sex, F/M (%)* | 15/11 (58/42) | 23/7 (77/23) | 0.219 | ||
Age, years | 36.4 (13) | 31.3–5.1 | 40.4 (15.2) | 35–5.4 | 0.229 |
BMI, kg/m2 | 26.5 (6.3) | 24.1–2.4 | 27 (6.2) | 24.8–2.2 | 0.494 |
Overweight, n (%) | 9 (35) | 10 (33.3) | 0.920 | ||
Obesity, n (%) | 4 (15) | 7 (23.3) | 0.455 | ||
Diabetes, n (%) | 1 (3.9) | 2 (6.7) | 0.640 | ||
Hypertension, n (%) | 1 (3.9) | 4 (13.3) | 0.214 | ||
Cardiovascular disease, n (%) | 1 (3.9) | 3 (10) | 0.373 | ||
Hepatic disease, n (%) | 2 (7.7) | 0 (0) | 0.122 | ||
Kidney disease, n (%) | 1 (3.9) | 0 (0) | 0.278 | ||
BCG vaccination, yes (%)* | 20 (77) | 21 (70) | 0.344 | ||
Smoker, n (%) | 3 (12) | 5 (16.7) | 0.584 | ||
Vital signs | |||||
Oxygen Saturation, % | 95.7 (1.1) | 95.3–0.4 | 95.9 (1.3) | 95.4–0.5 | 0.323 |
Heart rate, bpm | 73 (11) | 68.8–4.2 | 82.2 (14.7) | 76.9–5.3 | 0.154 |
Respiratory rate, bpm | 18.5 (1.1) | 18.1–0.4 | 18.4 (1.5) | 17.9–0.5 | 0.384 |
Systolic pressure, mmHg | 113 (15) | 106.8–5.7 | 119.4 (21) | 111.9–7.5 | 0.145 |
Diastolic pressure, mmHg | 73.2 (10) | 69.2–4 | 77.4 (11.8) | 73.2–4.2 | 0.858 |
Body temperature, °C | 36.4 (0.5) | 36.2–0.2 | 36.4 (0.5) | 36.2–0.2 | 0.349 |